Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Methods for preparing pleuripotent cardiovascular progenitor cells and maintaining cardiovascular differentiation capacity

A technology of precursor cells and pluripotent stem cells, which can be applied to non-embryonic pluripotent stem cells, artificially induced pluripotent cells, animal cells, etc., and can solve the problems of little understanding of regulation and molecular basis

Active Publication Date: 2014-06-04
SHANGHAI INST OF BIOLOGICAL SCI CHINESE ACAD OF SCI
View PDF3 Cites 11 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0005] However, simple and reproducible, efficient transformation of hPSCs into homogeneous CVPCs without cell sorting and under trophoblast-free / serum-free conditions remains challenging, and the regulation and molecular basis of self-renewal and differentiation decisions of CVPCs remain challenging. Still poorly understood, the stable expansion of HPSC-derived CVPCs in vitro to maintain their long-term self-renewal and directed differentiation potential into cardiovascular cells remains a major challenge in the field

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Methods for preparing pleuripotent cardiovascular progenitor cells and maintaining cardiovascular differentiation capacity
  • Methods for preparing pleuripotent cardiovascular progenitor cells and maintaining cardiovascular differentiation capacity
  • Methods for preparing pleuripotent cardiovascular progenitor cells and maintaining cardiovascular differentiation capacity

Examples

Experimental program
Comparison scheme
Effect test

preparation example Construction

[0085] The present invention also includes the cell group containing cardiovascular precursor cells obtained by the aforementioned preparation method. In the cell group, the number of cardiovascular precursor cells accounts for more than 70% of the total number of cells, preferably more than 80% of the total number of cells; more preferably more than 85% of the total number of cells (by surface markers SSEA1 or MESP1 positive cells count).

[0086] Once a cell population containing cardiovascular precursor cells has been obtained, the identification of cardiovascular precursor cells can be achieved using RT-PCR and other gene expression analysis techniques.

[0087] Cardiovascular precursor cells can be identified or isolated or enriched using methods known to those skilled in the art. More classical methods such as fluorescence-activated cell sorting (FACS) or magnetic cell sorting, that is, the use of antibodies against specific surface molecules of cardiovascular precursor...

Embodiment 1

[0193] Example 1. Efficient transformation of human pluripotent stem cells (hPSCs) into homogeneous CVPCs

[0194] To induce hPSCs towards a cardiovascular fate, the inventors screened important signal transduction pathways during mesoderm formation and subsequent cardiac differentiation, including Wnt, GSK3, FGF, BMP and Activin / Nodal. In order to make the conditions uniform, the inventors used a single cell-based differentiation method on the basis of a monolayer culture system, and added the Rho kinase inhibitor Y27632 in the first day of differentiation to improve the survival of the cells. After a series of systematic attempts, the inventors found that the joint addition of 25ng / ml BMP4, 50 μg / ml AA and 3 μM GSK3 inhibitor CHIR99021 (CHIR) (the mixture of these combined reagents is named CIM) can efficiently remove untreated drugs within 3 days. The differentiated human embryonic stem cell line H9 converted into a homogeneous cell population that mostly (88.9 ± 1.8%) expr...

Embodiment 2

[0197] Example 2. Long-term maintenance of self-renewal of hPSC-derived CVPCs

[0198] Proliferation and lineage determination of CVPCs are regulated by a delicate microenvironment and complex levels of multiple signal transduction pathways, including Wnt, FGF, BMP, Notch, Hedgehog, vascular endothelial growth factor (VEGF), platelet-derived growth factor (PDGF ), MEK, retinoic acid (RA), and Activin / Nodal. Therefore, under specific conditions in vitro, it is generally difficult to maintain the self-renewal and expansion of CVPCs. The inventors hypothesized that if the conditions that induce CVPC differentiation are concertedly eliminated, they should be able to maintain basal state self-renewal and continued proliferation. To verify it, the inventors selected 9 signaling pathway inhibitors together with the GSK3 inhibitor CHIR (CHIR99021) (Table 3) to verify their role in stimulating CVPC expansion. Clonogenicity was not observed in H9-derived CVPCs on day 3 of differentiat...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to methods for preparing pleuripotent cardiovascular progenitor cells and maintaining cardiovascular differentiation capacity and discloses a method for inducing and differentiating pluripotent stem cells into the pleuripotent cardiovascular progenitor cells for the first time. The method comprises the step of carrying out induction by utilizing ascorbic acid, a bone morphogenetic protein 4 and a glycogen synthase kinase-3 inhibitor. The invention further provides a method for stably culturing the pleuripotent cardiovascular progenitor cells. The method comprises the steps of enabling the pleuripotent cardiovascular progenitor cells to stably grow and carry out generation transfer by utilizing a BMP (bone morphogenetic protein) signal channel inhibitor, an activin / Nodal signal channel inhibitor and a glycogen synthase kinase-3 signal channel inhibitor. The pleuripotent cardiovascular progenitor cells prepared by utilizing the method can be further differentiated into cells including myocardial cells, vascular smooth muscle cells or vascular endothelial cells in a cardiovascular pedigree and can be applied to the treatment and myocardial regeneration research of heart diseases, the pharmaceutical cardiovascular cytotoxicity detection and the development of heart medicaments.

Description

technical field [0001] The invention belongs to the field of cell biology; more specifically, the application relates to methods for inducing pluripotent stem cells to derive pluripotent cardiovascular precursor cells and maintaining the cardiovascular differentiation ability of cardiovascular precursor cells. Background technique [0002] Human pluripotent stem cells (hPSCs), including human embryonic stem cells (ESCs) and induced pluripotent stem cells (iPSCs), because they can proliferate indefinitely in vitro and have the ability to differentiate The ability to form the major cell types of the heart provides a whole new opportunity for cardiovascular research, drug development and safety testing, and cell therapy-based regenerative medicine. However, in order to avoid the tumorigenicity of direct transplantation, such cells must be induced to differentiate into tissue precursor cells and tissue cells. Therefore, in the past ten years, researchers have made unremitting e...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C12N5/0735C12N5/074C12N5/077C12N5/071
Inventor 杨黄恬曹楠梁贺
Owner SHANGHAI INST OF BIOLOGICAL SCI CHINESE ACAD OF SCI
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com